Know Cancer

or
forgot password

The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study


Phase 4
20 Years
N/A
Not Enrolling
Both
H. Pylori Infection

Thank you

Trial Information

The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study


Inclusion Criteria:



- Patients are aged greater than 20 years who have persistent H. pylori infection after
one treatment and are willing to receive second line rescue regimens, respectively,
are considered eligible for enrollment.

Exclusion Criteria:

- Children and teenagers aged less than 20 years,

- History of gastrectomy,

- Gastric malignancy, including adenocarcinoma and lymphoma,

- Previous allergic reaction to antibiotics (amoxicillin, clarithromycin, levofloxacin)
and prompt pump inhibitors (esomeprazole),

- Contraindication to treatment drugs,

- Pregnant or lactating women, OR

- Severe concurrent disease.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Eradication rate will be evaluated according to Intent-to-treat (ITT) and per-protocol (PP) analyses

Outcome Time Frame:

2009/4/20

Safety Issue:

No

Principal Investigator

Jyh-Ming Liou, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Nationa Taiwan University Hospital

Authority:

Taiwan: Department of Health

Study ID:

200901041M

NCT ID:

NCT00885417

Start Date:

April 2009

Completion Date:

December 2010

Related Keywords:

  • H. Pylori Infection
  • Helicobacter pylori
  • sequential therapy
  • levofloxacin
  • clarithromycin
  • rescue
  • salvage
  • treatment failure
  • For those who fail from one standard eradication therapy for H. pylori infection
  • Helicobacter Infections

Name

Location